RECRUITING

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

Official Title

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Quick Facts

Study Start:2024-02-08

Study Completion:2026-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06423963

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age 18 years or older * Biopsy-proven pancreatic ductal adenocarcinoma (PDAC), borderline resectable at diagnosis * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection * Ability to read and speak English	* Regular engagement in RT (2x/week targeting all major muscle groups) * Screen failure for exercise safety based on PAR-Q * Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease * Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT * Numeric pain rating scale greater than or equal to a 7 out of 10 * Myopathic or rheumatologic disease that impacts physical function

Inclusion Criteria

Exclusion Criteria

* Age 18 years or older
* Biopsy-proven pancreatic ductal adenocarcinoma (PDAC), borderline resectable at diagnosis
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection
* Ability to read and speak English

* Regular engagement in RT (2x/week targeting all major muscle groups)
* Screen failure for exercise safety based on PAR-Q
* Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
* Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
* Numeric pain rating scale greater than or equal to a 7 out of 10
* Myopathic or rheumatologic disease that impacts physical function

Contacts and Locations

Study Contact

Morgan Bean

CONTACT

813-745-1786

morgan.bean@moffitt.org

Principal Investigator

Nathan Parker, PhD

PRINCIPAL_INVESTIGATOR

Moffitt Cancer Center

Pamela Hodul, MD

PRINCIPAL_INVESTIGATOR

Moffitt Cancer Center

Study Locations (Sites)

Moffitt Cancer Center

Tampa, Florida, 33612

United States

Collaborators and Investigators

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Nathan Parker, PhD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center
Pamela Hodul, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-08

Study Completion Date2026-02

Study Record Updates

Study Start Date2024-02-08

Study Completion Date2026-02

Terms related to this study

Additional Relevant MeSH Terms

Pancreatic Cancer